GlassScriptPhysician profile
Omer Raheem
NPI 1336436252
$147,869.69
in general payments reported to CMS, 2019-2025
21 companies · $3,016 in 2025
The $3,016 reported for 2025 was more than what 86% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,571 · 2020: $879 · 2021: $1,537 · 2022: $59K · 2023: $77K · 2024: $3,020 · 2025: $3,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $47K · Honoraria: $26K · Consulting Fee: $4,469 · Travel and Lodging: $4,236 · Food and Beverage: $2,422 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $44.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $46,609.14 |
| Honoraria | $25,500.00 |
| Consulting Fee | $4,469.42 |
| Travel and Lodging | $4,235.86 |
| Food and Beverage | $2,422.43 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $77,800.20 | 2019-2023 | Xyosted, Tlando, Nocdurna |
| Coloplast Corp | $54,438.55 | 2019-2024 | Titan |
| Acerus Pharmaceuticals Corporation | $6,476.20 | 2021-2022 | |
| Mylan INC. | $3,354.20 | 2024-2025 | Viagra |
| Boston Scientific Corporation | $2,957.22 | 2019-2024 | Ams 700, Rezum Generator, Moses 550 Dfl |
| Procept Biorobotics Corporation | $1,210.18 | 2019-2024 | Aquabeam Robotic System, Aquabeam System |
| Neotract INC. | $428.20 | 2020 | |
| Halozyme INC | $291.26 | 2023 | |
| Olympus America INC. | $238.17 | 2020-2022 | |
| Astellas Pharma US INC | $178.54 | 2019-2021 | |
| Innovation Technologies INC | $140.95 | 2023-2024 | Irrisept |
| Teleflex LLC | $138.77 | 2021 | |
| Aytu Biopharma, INC. | $61.42 | 2019 | |
| Clarus Therapeutics INC. | $27.25 | 2021 | |
| Tempus Ai, INC | $25.51 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $23.04 | 2020 | |
| Travere Therapeutics, INC. | $22.20 | 2019 | |
| Cook Medical LLC | $22.10 | 2019 | |
| Endo Pharmaceuticals INC. | $20.10 | 2020 | |
| Tolmar, INC. | $15.63 | 2025 | Jatenzo |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omer Raheem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.